Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


CHMP recommends approval Calquence for chronic lymphocytic leukaemia,- AstraZeneca

Written by | 26 Jul 2020 | Pharmacy

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Calquence (acalabrutinib), from AstraZeneca, intended for the treatment of chronic lymphocytic leukaemia (CLL).

Calquence will be available as 100 mg hard capsules. Acalabrutinib, a protein kinase inhibitor, acts by inhibiting the Bruton tyrosine kinase (BTK), thus preventing signalling for B-cell survival and proliferation and resulting in blocking cellular adhesion, trafficking, and chemotaxis. The benefits with Calquence are its ability to prolong progression-free survival when used on its own or in combination with obinutuzumab. The most common side effects are respiratory tract infections, headache bruising, contusion, diarrhoea, nausea, rash, musculoskeletal pain, fatigue, decreased haemoglobin and decreased platelets.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.